First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

被引：0
|
作者：
Mark, M. [1 ]
Froesch, P. [2 ]
Gysel, K. [3 ]
Rothschild, S. [4 ]
Addeo, A. [5 ]
Ackermann, C. [6 ]
Chiquet, S. [3 ]
Schneider, M. [3 ]
Ribi, K. [3 ]
Fischer, A. [1 ]
Bastian, S. [1 ]
von Moos, R. [7 ]
Joerger, M. [8 ]
Frueh, M. [8 ]
机构：
[1] Cantonal Hosp Graubunden, Oncol Hematol, Chur, Switzerland
[2] Cantonal Hosp Bellinzona, Oncol, Bellinzona, Switzerland
[3] SAKK, Coordinating Ctr, Bern, Switzerland
[4] Cantonal Hosp Baden, Oncol Hematol, Baden, Switzerland
[5] Geneva Univ Hosp, Oncol, Geneva, Switzerland
[6] Hosp Thun, Oncol Hematol, Thun, Switzerland
[7] Cantonal Hosp Graubunden, Tumor & Res Ctr, Chur, Switzerland
[8] Cantonal Hosp St Gallen, Oncol Hematol, St Gallen, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2023年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
218
引用
收藏
页码：7S / 7S
页数：1
相关论文
共 50 条
  • [31] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Marcelo Martin, Claudio
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.
    Furukawa, Masayuki
    Ueno, Makoto
    Sakai, Daisuke
    Ouchi, Kota
    Hamamoto, Yasuo
    Aikata, Hiroshi
    Ozaka, Masato
    Tsumura, Hidetaka
    Tsuji, Kunihiro
    Kubo, Shoji
    Nishina, Tomohiro
    Katanuma, Akio
    Morizane, Chigusa
    Ikeda, Masafumi
    Mizuno, Nobumasa
    Inagaki, Takashi
    Shioji, Kazuhiko
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 533 - 533
  • [33] A phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first-and second-line treatment for advanced non-small cell lung cancer (NSCLC)
    Zinner, R.
    Fossella, F. V.
    Kies, M. S.
    Herbst, R. S.
    Lu, C.
    Johnson, F. M.
    Bhat, S. V.
    Price, J. S.
    Cleeland, C.
    Wang, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer
    Smit, Jasper
    Borm, Frank J.
    Niemeijer, Anna-Larissa N.
    Huisman, Marc C.
    Hoekstra, Otto S.
    Boellaard, Ronald
    Oprea-Lager, Daniela E.
    Vugts, Danielle J.
    van Dongen, Guus A. M. S.
    de Wit-van der Veen, Berlinda J.
    Thunnissen, Erik
    Smit, Egbert F.
    de Langen, Adrianus J.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 686 - 693
  • [35] Biweekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2: A phase II study of the Galician Lung Cancer Group
    Vazquez-Estevez, S.
    Leon, L.
    Firvida, J. L.
    Grande, C.
    Vazquez, F.
    Salgado, M.
    Casal, J.
    Baron, F. J.
    Abal, J.
    Garcia, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
    Gounant, V.
    Greillier, L.
    Mascaux, C.
    Pinquie, F.
    Carmier, D.
    Moreau, L.
    Roch, B.
    Debieuvre, D.
    Dhalluin, X.
    Giroux-Leprieur, E.
    Berton, E.
    Rabeau, A.
    Raimbourg, J.
    Dixmier, A.
    Naltet, C.
    Khalil, A.
    Ezzeddine, L.
    Langlais, A.
    Morin, F.
    Duruisseaux, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S842 - S842
  • [37] Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center
    Spyratos, Dionisios G.
    Tsiouprou, Ioanna
    Tsartsianidou, Valentina
    Lampaki, Sophia
    Eleftheriadou, Ellada
    Domvri, Kalliopi
    Kontakiotis, Theodoros
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [38] Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center
    Tsiouprou, I.
    Tsartsianidou, V.
    Papaemmanouil, S.
    Pastelli, N.
    Lampaki, S.
    Eleftheriadou, E.
    Domvri, K.
    Kontakiotis, T.
    Spyratos, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Single-agent compared to combination first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2
    Bonomi, P.
    Villaflor, V. M.
    Oldham, F. B.
    Sandilac, L.
    Singer, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab
    Kerr, K. M.
    Perez, J.
    McGuire, K.
    Baker, B.
    Fang, F.
    Li, J.
    Wlasiuk, G.
    Li, S.
    Gao, B.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S590 - S591
12345